Treatments for Olfactory Dysfunction in COVID-19: A Systematic Review.

IF 1 Q3 OTORHINOLARYNGOLOGY International Archives of Otorhinolaryngology Pub Date : 2024-05-25 eCollection Date: 2024-10-01 DOI:10.1055/s-0044-1786046
Esmaeil Mehraeen, Soudabeh Yarmohammadi, Pegah Mirzapour, Seyed Saeed Tamehri Zadeh, Soheil Dehghani, Leila Molaeipour, Ayoob Molla, Elaheh Karimi, Faeze Abbaspour, SeyedAhmad SeyedAlinaghi
{"title":"Treatments for Olfactory Dysfunction in COVID-19: A Systematic Review.","authors":"Esmaeil Mehraeen, Soudabeh Yarmohammadi, Pegah Mirzapour, Seyed Saeed Tamehri Zadeh, Soheil Dehghani, Leila Molaeipour, Ayoob Molla, Elaheh Karimi, Faeze Abbaspour, SeyedAhmad SeyedAlinaghi","doi":"10.1055/s-0044-1786046","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction</b>  Olfactory dysfunction (OD) has emerged as a notable symptom among coronavirus disease 2019 (COVID-19) patients, with its prevalence varying among different populations. Recognizing the need to provide therapeutic solutions for these individuals, the present study seeks to comprehensively review the current evidence on potential underlying mechanisms and treatment modalities to manage OD in COVID-19 patients. <b>Objective</b>  To review the recent evidence on treatments for OD in COVID-19. From the beginning of the study until August 2nd, 2023, we conducted a systematic search on four electronic databases, PubMed, Scopus, Embase, and Web of Science, to find relevant publications. <b>Data Synthesis</b>  In the present study, 37 articles were selected for data extraction and included in the final review. The total number of patients was of 3,560 (2,098 female and 1,462 male subjects). The predominant disorders reported were hyposmia, anosmia, and parosmia. In most of the studies, the pre and postintervention assessments were the same, except for one study, in which the pre-intervention assessment of the disorder was through the SST, Sniffin' Sticks Test (SST), and the post-intervention assessment was through the Visual Analog Scale (VAS) and the 22-item Sinonasal Outcome Test (SNOT-22). The findings suggest olfactory training (OT), ivermectin, palmitoylethanolamide, luteolin, and systemic corticosteroids, in combination with topical corticosteroids, are potential therapies for COVID-19 patients with olfactory impairment. <b>Conclusion</b>  Although the review suggested several medications for OD treatment, further research must delve into the specific impact of OT, a non-pharmacological modality, regarding the mitigation of OD. By continuing to investigate and refine these therapeutic approaches, we can better support COVID-19 patients and improve their quality of life while navigating the challenges posed by OD.</p>","PeriodicalId":13731,"journal":{"name":"International Archives of Otorhinolaryngology","volume":"28 4","pages":"e728-e743"},"PeriodicalIF":1.0000,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11511580/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Otorhinolaryngology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0044-1786046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction  Olfactory dysfunction (OD) has emerged as a notable symptom among coronavirus disease 2019 (COVID-19) patients, with its prevalence varying among different populations. Recognizing the need to provide therapeutic solutions for these individuals, the present study seeks to comprehensively review the current evidence on potential underlying mechanisms and treatment modalities to manage OD in COVID-19 patients. Objective  To review the recent evidence on treatments for OD in COVID-19. From the beginning of the study until August 2nd, 2023, we conducted a systematic search on four electronic databases, PubMed, Scopus, Embase, and Web of Science, to find relevant publications. Data Synthesis  In the present study, 37 articles were selected for data extraction and included in the final review. The total number of patients was of 3,560 (2,098 female and 1,462 male subjects). The predominant disorders reported were hyposmia, anosmia, and parosmia. In most of the studies, the pre and postintervention assessments were the same, except for one study, in which the pre-intervention assessment of the disorder was through the SST, Sniffin' Sticks Test (SST), and the post-intervention assessment was through the Visual Analog Scale (VAS) and the 22-item Sinonasal Outcome Test (SNOT-22). The findings suggest olfactory training (OT), ivermectin, palmitoylethanolamide, luteolin, and systemic corticosteroids, in combination with topical corticosteroids, are potential therapies for COVID-19 patients with olfactory impairment. Conclusion  Although the review suggested several medications for OD treatment, further research must delve into the specific impact of OT, a non-pharmacological modality, regarding the mitigation of OD. By continuing to investigate and refine these therapeutic approaches, we can better support COVID-19 patients and improve their quality of life while navigating the challenges posed by OD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗 COVID-19 嗅觉功能障碍:系统回顾。
引言 嗅觉功能障碍(OD)已成为冠状病毒病 2019(COVID-19)患者的一个显著症状,其发病率因人群而异。本研究认识到为这些患者提供治疗方案的必要性,旨在全面回顾有关潜在潜在机制和治疗方法的现有证据,以控制 COVID-19 患者的嗅觉障碍。目的 回顾 COVID-19 患者 OD 治疗的最新证据。从研究开始到 2023 年 8 月 2 日,我们在 PubMed、Scopus、Embase 和 Web of Science 四个电子数据库中进行了系统检索,以查找相关出版物。数据综述 本研究共选取了 37 篇文章进行数据提取,并纳入最终综述。患者总数为 3,560 人(其中女性 2,098 人,男性 1,462 人)。报告的主要病症是嗅觉减退、嗅觉缺失和嗅觉减退。在大多数研究中,干预前和干预后的评估是相同的,只有一项研究例外,其中干预前的失调评估是通过嗅棒测试(SST)进行的,干预后的评估是通过视觉模拟量表(VAS)和 22 项鼻窦结果测试(SNOT-22)进行的。研究结果表明,嗅觉训练 (OT)、伊维菌素、棕榈酰乙醇酰胺、木犀草素和全身性皮质类固醇与局部皮质类固醇相结合,是治疗 COVID-19 患者嗅觉障碍的潜在疗法。结论 虽然综述提出了几种治疗嗅觉障碍的药物,但进一步的研究必须深入探讨 OT 这种非药物疗法对缓解嗅觉障碍的具体影响。通过继续研究和改进这些治疗方法,我们可以更好地支持 COVID-19 患者,在应对 OD 带来的挑战的同时提高他们的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
84
审稿时长
12 weeks
期刊最新文献
Audiological Characterization of Individuals with Cornelia de Lange Syndrome. Do Anatomical Variations of Sphenoid Sinus Influence Sella Exposure and Residual Disease in Pituitary Surgery? - A Study in an Indian Population. Dysphagia: Focus in Diagnosis. Efficacy of Expansion Pharyngoplasty without Drug-induced Sleep Endoscopy Screening in Obstructive Sleep Apnea. Results of a New Treatment Protocol for Sudden Sensorineural Hearing Loss Using Betamethasone for Intratympanic Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1